

performed through an additional polarizer that separates the specularly reflected light from the diffusely backscattered light, which originates in deeper tissue layers, allowing enhanced imaging of the hidden subsurface tissue structure (texture). The region of interest is illuminated by linearly polarized light, and backscattered light passes through the polarization filter to be detected by a digital camera. A custom optical design preserves the polarization state of the backscattered light in the microscope, without interfering with the standard optical path and operation of the microscope, including its binocular system. Special algorithms to visualize regions of statistical similarity in the image have been developed. Though the diffusely backscattered light presents only a small fraction of the detected light, its analysis, using the customized design and image processing procedures, provides useful information about internal structures of biological tissues. The polarimetric accessory includes a linear polarizer for the illuminating beam, two beam splitters for preserving polarization state, lens system for imaging, polarization analyzer, band-pass optical filter, digital camera, and electronic triggering system.

*Potential Commercial Applications:* Gynecological examinations

*Competitive Advantages:*

- Image quality
- Resolution of tissue structures at close microscopic distances

*Development Stage:* Prototype

*Inventors:* Amir Gandjbakhche (NICHD), Victor Chernomordik (NICHD), Moinuddin Hassan (NICHD), Alexander Sviridov (NICHD), Zachary Alissi (NICHD), Paul Smith (NIBIB), Albert Boccara (NICHD)

*Publications:*

1. Jacques SL, et al. Imaging superficial tissues with polarized light. *Lasers Surg Med.* 2000;26(2):119–29. [PMID 10685085]
2. Jacques SL, et al. Imaging skin pathology with polarized light. *J Biomed Opt.* 2002 Jul;7(3):329–40. [PMID 12175282]
3. Ramella-Roman JC, et al. Design, testing, and clinical studies of a handheld polarized light camera. *J Biomed Opt.* 2004 Nov–Dec;9(6):1305–10. [PMID 15568952]
4. Sviridov AP, et al. “Analysis of Biological Tissue Textures Using Measurements of Backscattered Polarized Light” (presented at the Optical Society of America—Biomedical Optics Topical Meeting, Fort Lauderdale, Florida, March 2006).
5. Sviridov AP, et al. Visualization of biological texture using correlation

coefficient images. *J Biomed Opt.* 2006 Nov–Dec;11(6):060504. [PMID 17212522]

*Intellectual Property:* HHS Reference No. E–084–2012—US Provisional Patent Application No. 61/620,295 filed 04 Apr 2012

*Licensing Contact:* Michael A. Shmilovich, Esq., CLP; 301–435–5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov)

### **CpG Oligonucleotides Treatment To Prevent Chemotherapy-Induced Pulmonary Toxicity**

*Description of Technology:* Bleomycin (BLM) is a chemotherapy agent used to treat multiple types of cancer, but its side effects are life threatening for some patients. About 20% of patients undergoing BLM chemotherapy develop interstitial pneumonitis which may develop to life threatening fibrosis. In such cases, BLM chemotherapy cannot be continued.

This invention identifies a method of pre-treatment using immunostimulatory CpG Oligonucleotide (ODN) molecules to prevent chemotherapy-induced pulmonary toxicity. Administration of certain ODN molecules induces inflammation via stimulation of inflammatory genes (Toll-like receptor 9/TLR9). This stimulation is subsequently down-regulated. This technology makes use of this counter regulatory mechanism to reduce the side effects of chemotherapy agents, such as BML. A properly timed pre-administration of ODN molecules, prior to BML therapy, prevents the lethal side effect of BLM-induced pulmonary inflammation and down-regulates promoters of BLM toxicity (IL–17A and TGF-beta1). Because toxicity from pulmonary inflammation is a side effect limiting use of many chemotherapeutic agents and ODN molecules are relatively inexpensive and have a favorable safety profile, this technology may be useful to improve treatment protocols for many chemotherapy agents.

*Potential Commercial Applications:* Therapeutic to reduce harmful side effects of pulmonary inflammation caused by chemotherapy.

*Competitive Advantages:*

- Pulmonary toxicity during chemotherapy is dangerous side effect, this technology uses ODN molecules that are relatively inexpensive and have a favorable safety profile to reduce this side effect.

- This technology may increase the safety and availability of many chemotherapy treatments.

*Development Stage:*

- Early-stage
- In vivo data available (animal)

*Inventors:* Dennis Klinman and Takeshi Kinjo (NCI)

*Publication:* Kinjo T, et al. The counter regulatory response induced by CpG oligonucleotides prevents bleomycin induced pneumopathy. *Respir Res.* 2012 Jun 18;13:47. [PMID 22708497]

*Intellectual Property:* HHS Reference No. E–077–2012/0—U.S. Provisional Patent Application No. 61/643,088 filed 04 May 2012

*Licensing Contact:* Edward (Tedd) Fenn; 301–435–5031; [fenned@mail.nih.gov](mailto:fenned@mail.nih.gov)

*Collaborative Research Opportunity:* The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize CpG oligonucleotides for use to down-modulate inflammatory reactions. For collaboration opportunities, please contact John D. Hewes, Ph.D. at [hewesj@mail.nih.gov](mailto:hewesj@mail.nih.gov).

Dated: April 1, 2013.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2013–07917 Filed 4–4–13; 8:45 am]

**BILLING CODE 4140–01–P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute on Aging; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; Management of the Primate Aging Database

*Date:* April 23, 2013.

*Time:* 1:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Elaine Lewis, Ph.D., Scientific Review Branch, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7707, [elainelewis@nia.nih.gov](mailto:elainelewis@nia.nih.gov).  
(Catalogue of Federal Domestic Assistance Program No. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: April 1, 2013.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-07904 Filed 4-4-13; 8:45 am]

**BILLING CODE 4140-01-P**

## Department of Health and Human Services

### National Institutes of Health

#### Office of the Director, National Institutes of Health, Notice of Meeting

Notice is hereby given of a meeting scheduled by the Deputy Director for Intramural Research at the National Institutes of Health (NIH) with the Chairpersons of the Boards of Scientific Counselors. The Boards of Scientific Counselors are advisory groups to the Scientific Directors of the Intramural Research Programs at the NIH. This meeting will take place on April 29, 2013, from 10:00 a.m. to 2:00 p.m., at the NIH, 1 Center Drive, Bethesda, MD, Building 1, Room 151. The meeting will include a discussion of policies and procedures that apply to the regular review of NIH intramural scientists and their work.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Margaret McBurney, Office of Intramural Research, NIH, Building 1, Room 160, Telephone (301) 496-1921, Fax (301) 402-4273, or email [mmcburney@od.nih.gov](mailto:mmcburney@od.nih.gov) in advance of the meeting.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Dated: March 29, 2013.

**Anna Snouffer,**

*Deputy Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-07906 Filed 4-4-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review Amended; Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, March 29, 2013, 01:00 p.m. to March 29, 2013, 05:00 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, 20817 which was published in the **Federal Register** on March 12, 2013, 78 FR Pg. 15729.

The meeting will be held on April 4, 2013 instead of March 29, 2013 at 1:00 p.m. and will end at 5:00 p.m. The meeting location remains the same. The meeting is closed to the public.

Dated: March 29, 2013.

**Carolyn A. Baum,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-07899 Filed 4-4-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Diabetes, Metabolism and Obesity.

*Date:* April 11, 2013.

*Time:* 8:00 a.m. to 9:00 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Dianne Hardy, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6175, MSC 7892, Bethesda, MD 20892, 301-435-1154, [dianne.hardy@nih.gov](mailto:dianne.hardy@nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 1, 2013.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-07900 Filed 4-4-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; Hypoxia and Respiration.

*Date:* April 30, 2013.

*Time:* 9:00 a.m. to 11:30 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Room 7206, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Shelley S. Sehnert, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7206, Bethesda, MD 20892-7924, 301-435-0303, [ssehnert@nhlbi.nih.gov](mailto:ssehnert@nhlbi.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung